Jan Schmielau - Concepedia

Author

Jan Schmielau

University of Pittsburgh

Also Known As

J Schmielau, J. Schmielau, Jan Schmielau

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

University of Pittsburgh

About

Jan Schmielau is an author at University of Pittsburgh specializing in immunology, medicine, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.1K
2	Immunology	5	5	1.1K
3	Pathology	3	3	194
4	Cell Biology	2	2	900
5	Health Sciences	1	1	13

Jan Schmielau

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Jan Schmielau, Olivera J. Finn PubMed T-regulatory CellImmunologyBlood CellImmunotherapyOxidative Stress	2001	872
Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Wolff Schmiegel, Christian Roeder, Jan Schmielau, Proceedings of the National Academy of Sciences Tgf-alpha ProteinSignal TransductionSignaling PathwayPancreatic CancerCell Signaling	1993	104
Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Jan Schmielau, Michael A. Nalesnik, Olivera J. Finn PubMed T-regulatory CellImmunologyImmune RegulationPathologyImmunologic Mechanism	2001	62
Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution Nehad M. Alajez, Jan Schmielau, Mark D. Alter, Blood	2005	43
Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer Wolff Schmiegel, Jan Schmielau, Doris Henne‐Bruns, Proceedings of the National Academy of Sciences Tumor Necrosis FactorCancer ImmunosurveillancePancreatic CancerMab SpecificMedicine	1997	28
Work‐related medical rehabilitation in patients with cancer—Postrehabilitation results from a cluster‐randomized multicenter trial David Fauser, Julian Wienert, T. Beinert, Cancer	2019	18
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma Jan Schmielau, Christian Teschendorf, Matthias König, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyTransplantationMedicineMalignant Blood DisorderHematology	2005	13

Page 1